Overview

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of CCI-779 in treating patients who have mantle cell non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Everolimus
Sirolimus